Contributions of cholinergic receptor muscarinic 1 and CYP1A2 gene variants on the effects of plasma ratio of clozapine/N-desmethylclozapine on working memory in schizophrenia
Authors:
- 4 November 2020
- journal article
- research article
- Published by SAGE Publications in Journal of Psychopharmacology
- Vol. 35 (1) , 31-39
Abstract
Clozapine has heterogenous efficacy in enhancing working memory in schizophrenia. We have previously hypothesized that this is due to opposing effects of clozapine and its metabolite, N-desmethylclozapine, at the muscarinic M1 receptor and demonstrated that a lower clozapine/N-desmethylclozapine ratio is associated with better working memory than clozapine or N-desmethylclozapine levels alone. In this study, we expanded the above hypothesis to explore whether genetic variation in the cholinergic receptor muscarinic 1 gene, encoding the M1 receptor, affects the relationship between clozapine/N-desmethylclozapine and working memory. Further, we explored whether CYP1A2 gene variants affect the ratio of clozapine/N-desmethylclozapine and by this, working memory performance. We evaluated two functionally significant single nucleotide polymorphisms, rs1942499 and rs2075748, in cholinergic receptor muscarinic 1, with the haplotype T-A associated with lower transcriptional activity than the haplotype C-G. Further, we examined CYP1A2 *1F, with *1F/*1F conferring high inducibility in the presence of smoking. In a sample of 30 patients with schizophrenia on clozapine monotherapy, clozapine/N-desmethylclozapine was correlated with working memory only in non-carriers of the haplotype T-A of the cholinergic receptor muscarinic 1 gene. Interaction of CYP1A2 genotype and smoking status significantly affected clozapine concentrations, but there were no significant effects of CYP1A2 genotype and smoking status on the relationship between clozapine/N-desmethylclozapine on working memory. Our finding that the relationship between clozapine/N-desmethylclozapine and working memory is specific to patients with potentially higher transcription of M1 receptor (i.e. non-carriers of the haplotype T-A of cholinergic receptor muscarinic 1) supports a cholinergic mechanism underlying this relationship.Keywords
This publication has 34 references indexed in Scilit:
- CYP1A2*1F Polymorphism Decreases Clinical Response to Clozapine in Patients with SchizophreniaKlinik Psikofarmakoloji Bülteni / Bulletin of Clinical Psychopharmacology, 2011
- Working memory in schizophrenia: a meta-analysisPsychological Medicine, 2008
- Ancestry Estimation and Correction for Population Stratification in Molecular Epidemiologic Association StudiesCancer Epidemiology, Biomarkers & Prevention, 2008
- Cognitive deficits and functional outcome in schizophreniaNeuropsychiatric Disease and Treatment, 2006
- Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICSSchizophrenia Research, 2004
- Nonresponse to Clozapine and Ultrarapid CYP1A2 ActivityJournal of Clinical Psychopharmacology, 2004
- Very High Cytochrome P4501A2 Activity and Nonresponse to ClozapineArchives of General Psychiatry, 1998
- Cholinergic stimulation alters performance and task-specific regional cerebral blood flow during working memoryProceedings of the National Academy of Sciences, 1997
- Determination of clozapine and its major metabolites in human plasma and red blood cells by high-performance liquid chromatography with ultraviolet absorbance detectionJournal of Chromatography B: Biomedical Sciences and Applications, 1997
- Determination of clozapine and its N-demethylated metabolite in plasma by use of gas chromatography-mass spectrometry with single ion detectionPsychopharmacology, 1988